Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Kyorin Pharma Enters into Collaborative Agreement with Microbial Chemistry Research Foundation 12
Kyorin Pharma Enters into Development and Distribution Agreement with Faes Farma 13
MSD Enters into Distribution Agreement with Kyorin Pharma 14
MSD Enters into Agreement with Kyorin Pharma 15
Kyorin Pharma to Enter into Co-Promotion Agreement with Kaken Pharma 16
Kissei Pharma Enters into Agreement with Kyorin Pharma 17
Kyorin Pharma Enters into Co-Development Agreement with PeptiDream 18
Kyorin Pharma Enters into Co-Marketing Agreement with Yoshida Pharma 19
Kyorin Pharma Amends Co-Marketing Agreement with MSD 20
Eisai Enters into Agreement with Kyorin 21
Kyorin Pharma Enters Into Research Agreement With BioLeap 22
Licensing Agreements 23
Kyorin Pharma Enters into Licensing Agreement with Sanwa Kagaku 23
Kyorin Pharma Enters into Licensing Agreement with Merck 24
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 25
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 26
Synmosa Biopharma Enters into Licensing Agreement with Kyorin Pharma 27
R-Pharm Enters into Licensing Agreement with Kyorin Pharma for Imidafenacin 28
Kyorin Pharma Enters into Licensing Agreement with Merck 29
Asset Transactions 30
Galderma Acquires Pekiron Cream From Kyorin Pharma 30
Kyorin Pharmaceutical Co Ltd – Key Competitors 31
Kyorin Pharmaceutical Co Ltd – Key Employees 32
Kyorin Pharmaceutical Co Ltd – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Product News 34
11/01/2017: MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 28th International Symposium on ALS/MND in Boston, MA, USA 34
10/28/2017: Cleveland Clinic trial on drug shows promise in slowing progressive multiple sclerosis 35
04/25/2017: MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology 69th Annual Meeting in Boston 36
04/09/2017: MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois 38
02/27/2017: MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies in Zurich, Switzerland 39
02/07/2017: MediciNova Announces MN-166 ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 69th Annual Meeting in Boston 40
Clinical Trials 41
Oct 26, 2017: MediciNova Announces Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS: Achieved Both Primary Endpoints including a Significant Reduction in Whole Brain Atrophy and Safety and Tolerability 41
Sep 19, 2017: MediciNova Announces the Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence 42
Aug 30, 2017: MediciNova Announces the Abstract from the MN-166 SPRINT-MS Phase 2b Study in Progressive MS – including Top Line Data – was Selected as a Platform Presentation for Late-Breaking Presentation at the 7th Joint ECTRIMS – ACTRIMS Meeting on October 28, 2017 in Paris, France 43
Jun 05, 2017: MediciNova Announces Positive Results from a Glioblastoma Animal Model Study Presented at the 2017 American Society of Clinical Oncology Annual Meeting 44
Feb 06, 2017: MediciNova Announces Positive Findings from Completed Trial of MN-166 (ibudilast) in Methamphetamine Dependence Presented at the 50th Winter Conference on Brain Research 45
Jan 23, 2017: MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kyorin Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kyorin Pharma Enters into Collaborative Agreement with Microbial Chemistry Research Foundation 12
Kyorin Pharma Enters into Development and Distribution Agreement with Faes Farma 13
MSD Enters into Distribution Agreement with Kyorin Pharma 14
MSD Enters into Agreement with Kyorin Pharma 15
Kyorin Pharma to Enter into Co-Promotion Agreement with Kaken Pharma 16
Kissei Pharma Enters into Agreement with Kyorin Pharma 17
Kyorin Pharma Enters into Co-Development Agreement with PeptiDream 18
Kyorin Pharma Enters into Co-Marketing Agreement with Yoshida Pharma 19
Kyorin Pharma Amends Co-Marketing Agreement with MSD 20
Eisai Enters into Agreement with Kyorin 21
Kyorin Pharma Enters Into Research Agreement With BioLeap 22
Kyorin Pharma Enters into Licensing Agreement with Sanwa Kagaku 23
Kyorin Pharma Enters into Licensing Agreement with Merck 24
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 25
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 26
Synmosa Biopharma Enters into Licensing Agreement with Kyorin Pharma 27
R-Pharm Enters into Licensing Agreement with Kyorin Pharma for Imidafenacin 28
Kyorin Pharma Enters into Licensing Agreement with Merck 29
Galderma Acquires Pekiron Cream From Kyorin Pharma 30
Kyorin Pharmaceutical Co Ltd, Key Competitors 31
Kyorin Pharmaceutical Co Ltd, Key Employees 32
Kyorin Pharmaceutical Co Ltd, Other Locations 33
Kyorin Pharmaceutical Co Ltd, Subsidiaries 33
List of Figures
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
【免責事項】
http://www.globalresearch.jp/disclaimer